The emerging use of IMRT for treatment of cervical cancer

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 8, Issue 12, 2010, Pages 1425-1434

  Loiselle, Christopher ^a   Koh, Wui Jin ^a  

^a UNIVERSITY OF WASHINGTON MEDICAL CENTER   (United States)

Author keywords

Cervical cancer; Cervix cancer; IMRT; Radiation therapy; Radiotherapy

Indexed keywords

BRACHYTHERAPY; CANCER ADJUVANT THERAPY; DOSIMETRY; GASTROINTESTINAL TOXICITY; HEMATOLOGIC DISEASE; HUMAN; HYSTERECTOMY; INTENSITY MODULATED RADIATION THERAPY; REVIEW; TUMOR GROWTH; UTERINE CERVIX CANCER;

EID: 78951479004     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: 10.6004/jnccn.2010.0106     Document Type: Review

References (38)

1. American Cancer Society. Cancer Facts & Figures 2010. Available at: http://www.cancer.org/acs/groups/content/@ epidemiologysurveilance/documents/ document/acspc-026238.pdf. Accessed November 3, 2010.
2. American Cancer Society. Global Cancer Facts & Figures 2007. Available at: http://www.cancer.org/acs/groups/content/@nho/ documents/document/globalfactsandfigures2007rev2p.pdf. Accessed November 4, 2010.
3. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:1154-1161.
4. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 1999;340:1137-1143.
5. Peters WA III, Liu PY, Barrett RJ II, et al. Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606-1613.
6. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 1999;340:1144-1153.
7. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and Southwest Oncology Group study. J Clin Oncol 1999;17:1339-1348.
8. Kirwan JM, Symonds P, Green JA, et al. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol 2003;68:217-226.
9. Nout RA, Putter H, Jurgenliemk-Schulz IM, et al. Quality of life after pelvic radiotherapy or vaginal brachytherapy for endometrial cancer: first results of the randomized PORTEC-2 trial. J Clin Oncol 2009;27:3547-3556.
10. Zunino S, Rosato O, Lucino S, et al. Anatomic study of the pelvis in carcinoma of the uterine cervix as related to the box technique. Int J Radiat Oncol Biol Phys 1999;44:53-59.
11. Mell LK, Mehrotra AK, Mundt AJ. Intensity-modulated radiation therapy use in the U.S., 2004. Cancer 2005;104:1296-1303.
12. Mell LK, Roeske JC, Mundt AJ. A survey of intensity-modulated radiation therapy use in the United States. Cancer 2003;98:204-211.
13. Fiorino C, Valdagni R, Rancati T, et al. Dose-volume effects for normal tissues in external radiotherapy: pelvis. Radiother Oncol 2009;93:153-167.
14. Portelance L, Chao KS, Grigsby PW, et al. Intensity-modulated radiation therapy (IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer receiving pelvic and paraaortic irradiation. Int J Radiat Oncol Biol Phys 2001;51:261-266.
15. Roeske JC, Mundt AJ, Halpern H, et al. Late rectal sequelae following definitive radiation therapy for carcinoma of the uterine cervix: a dosimetric analysis. Int J Radiat Oncol Biol Phys 1997;37:351-358.
16. Roeske JC, Lujan A, Rotmensch J, et al. Intensity-modulated whole pelvic radiation therapy in patients with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2000;48:1613-1621.
17. Lujan AE, Mundt AJ, Yamada SD, et al. Intensity-modulated radiotherapy as a means of reducing dose to bone marrow in gynecologic patients receiving whole pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2003;57:516-521.
18. Ahamad A, D'Souza W, Salehpour M, et al. Intensity-modulated radiation therapy after hysterectomy: comparison with conventional treatment and sensitivity of the normal-tissue-sparing effect to margin size. Int J Radiat Oncol Biol Phys 2005;62:1117-1124.
19. Ahmed RS, Kim RY, Duan J, et al. IMRT dose escalation for positive para-aortic lymph nodes in patients with locally advanced cervical cancer while reducing dose to bone marrow and other organs at risk. Int J Radiat Oncol Biol Phys 2004;60:505-512.
20. Mundt AJ, Roeske JC, Lujan AE, et al. Initial clinical experience with intensity-modulated whole-pelvis radiation therapy in women with gynecologic malignancies. Gynecol Oncol 2001;82:456-463.
21. Mundt AJ, Lujan AE, Rotmensch J, et al. Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002;52:1330-1337.
22. Brixey CJ, Roeske JC, Lujan AE, et al. Impact of intensity-modulated radiotherapy on acute hematologic toxicity in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002;54:1388-1396.
23. Mundt AJ, Mell LK, Roeske JC. Preliminary analysis of chronic gastrointestinal toxicity in gynecology patients treated with intensity-modulated whole pelvic radiation therapy. Int J Radiat Oncol Biol Phys 2003;56:1354-1360.
24. Salama JK, Mundt AJ, Roeske J, et al. Preliminary outcome and toxicity report of extended-field, intensity-modulated radiation therapy for gynecologic malignancies. Int J Radiat Oncol Biol Phys 2006;65:1170-1176.
25. Beriwal S, Gan GN, Heron DE, et al. Early clinical outcome with concurrent chemotherapy and extended-field, intensity-modulated radiotherapy for cervical cancer. Int J Radiat Oncol Biol Phys 2007;68:166-171.
26. Gerszten K, Colonello K, Heron DE, et al. Feasibility of concurrent cisplatin and extended-field radiation therapy (EFRT) using intensity-modulated radiotherapy (IMRT) for carcinoma of the cervix. Gynecol Oncol 2006;102:182-188.
27. Buchali A, Koswig S, Dinges S, et al. Impact of the filling status of the bladder and rectum on their integral dose distribution and the movement of the uterus in the treatment planning of gynaecological cancer. Radiother Oncol 1999;52:29-34.
28. Han Y, Shin EH, Huh SJ, et al. Interfractional dose variation during intensity-modulated radiation therapy for cervical cancer assessed by weekly CT evaluation. Int J Radiat Oncol Biol Phys 2006;65:617-623.
29. Lim K, Kelly V, Stewart J, et al. Pelvic radiotherapy for cancer of the cervix: is what you plan actually what you deliver? Int J Radiat Oncol Biol Phys 2009;74:304-312.
30. Chan P, Dinniwell R, Haider MA, et al. Inter- and intrafractional tumor and organ movement in patients with cervical cancer undergoing radiotherapy: a cinematic-MRI point-of-interest study. Int J Radiat Oncol Biol Phys 2008;70:1507-1515.
31. van de Bunt L, Jurgenliemk-Schulz IM, de Kort GA, et al. Motion and deformation of the target volumes during IMRT for cervical cancer: what margins do we need? Radiother Oncol 2008;88:233-240.
32. Lee CM, Shrieve DC, Gaffney DK. Rapid involution and mobility of carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2004;58:625-630.
33. van de Bunt L, van der Heide UA, Ketelaars M, et al. Conventional, conformal, and intensity-modulated radiation therapy treatment planning of external beam radiotherapy for cervical cancer: the impact of tumor regression. Int J Radiat Oncol Biol Phys 2006;64:189-196.
34. Beadle BM, Jhingran A, Salehpour M, et al. Cervix regression and motion during the course of external beam chemoradiation for cervical cancer. Int J Radiat Oncol Biol Phys 2009;73:235-241.
35. Jhingran A, Winter K, Portelance L, et al. A phase II study of intensity modulated radiation therapy (IMRT) to the pelvic for post-operative patients with endometrial carcinoma (RTOG 0418). Int J Rad Oncl Biol Phys 2008;72:S16.
36. Lim K, Small W Jr, Portelance L, et al. Consensus guidelines for delineation of clinical target volume for intensity-modulated pelvic radiotherapy for the definitive treatment of cervix cancer. Int J Radiat Oncol Biol Phys, in press.
37. Mell LK, Kochanski JD, Roeske JC, et al. Dosimetric predictors of acute hematologic toxicity in cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy. Int J Radiat Oncol Biol Phys 2006;66:1356-1365.
38. Mell LK, Tiryaki H, Ahn KH, et al. Dosimetric comparison of bone marrow-sparing intensity-modulated radiotherapy versus conventional techniques for treatment of cervical cancer. Int J Radiat Oncol Biol Phys 2008;71:1504-1510.